TargetMol

14-Deoxy-11,12-didehydroandrographolide

Product Code:
 
TAR-TQ0185
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TQ0185-1mg1mg£137.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0185-5mg5mg£229.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0185-10mg10mg£303.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0185-25mg25mg£463.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0185-50mg50mg£643.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0185-100mg100mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TQ0185-500mg500mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
14-Deoxy-11,12-didehydroandrographolide has hypotensive, anti-inflammatory, anti-asthma, and anti-cancer actions. It can inhibit NF-κB activation.
CAS:
42895-58-9
Formula:
C20H28O4
Molecular Weight:
332.44
Pathway:
NF-κb
Purity:
0.9945
SMILES:
[H][C@]12CCC(=C)[C@@H](C=CC3=CCOC3=O)[C@]1(C)CCC(O)[C@@]2(C)CO
Target:
NF-κB

References

Guan SP, et al. Protective role of 14-deoxy-11,12-didehydroandrographolide, a noncytotoxic analogue ofandrographolide, in allergic airway inflammation. J Nat Prod. 2011 Jun 24;74(6):1484-90.